+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Implantable Cardioverter Defibrillator Market Size, Share & Industry Trends Analysis Report By Type, By Product Type, By NYHA Class, By End-Use (Hospitals, Ambulatory Surgical Centers), By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • October 2023
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5935344
Description Jump to:
The Global Implantable Cardioverter Defibrillator Market size is expected to reach $5.6 billion by 2030, rising at a market growth of 6.1% CAGR during the forecast period.

The rising incidence of cardiovascular diseases, like heart failure and arrhythmias, contributes to the growing demand for ICDs. Therefore, Dual Chamber ICDs segment would generate $1,164.3 million revenue in the market in 2022. As the global population ages and lifestyle-related risk factors continue to rise, the prevalence of these conditions is expected to increase. CVD, including coronary artery disease and heart failure, is often associated with an increased risk of arrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF). Some of the factors impacting the market are expansion of indications for ICDs, development of MRI-compatible ICDs and high cost and limited accessibility.



Patients with ARVC at risk of ventricular arrhythmias candidates for ICD implantation. ARVC is a rare genetic disorder that affects the heart muscle and can lead to arrhythmias. Patients with inherited LQTS, associated with a higher risk of life-threatening arrhythmias, are considered for ICD therapy if they have experienced syncopal episodes or have a history of cardiac arrest. Brugada syndrome is another inherited arrhythmia disorder that can lead to sudden cardiac arrest. Additionally, the availability of MRI-compatible ICDs has significantly improved patient care by enabling individuals with ICDs to undergo essential MRI scans without needing device removal or the associated risks of potential device interactions during the scan. Additionally, the introduction of MRI-compatible ICDs expanded the ICD potential patient population. Patients often prefer Expanding indications for implantable cardioverter defibrillators (ICDs) have significantly developed the implantable cardioverter defibrillator market and the development of MRI-compatible ICDs represents a significant step forward in patient care, allowing individuals with ICDs to access essential MRI scans without compromising cardiac therapy. Thus, due to the following factors the market will expand.

However, the high cost of ICDs can create financial barriers for some patients, particularly those without adequate health insurance coverage or those living in regions with limited healthcare services. Socioeconomic disparities and disparities in healthcare access can affect who has access to ICD therapy. Some underserved populations face greater challenges in accessing ICDs. Access to specialized healthcare facilities and trained cardiac electrophysiologists who perform ICD implantation procedures are limited in rural or underserved areas. Geographic disparities can affect access to ICD therapy. The cost and accessibility of implantable cardioverter defibrillators are significant challenges in the healthcare landscape.

Furthermore, during the early stages of the pandemic, many hospitals and healthcare facilities postponed elective procedures, including ICD implantations, to prioritize COVID-19 patients and conserve resources. This led to a decline in ICD implantations in some regions. The pandemic accelerated the adoption of remote monitoring technology for ICDs. With in-person visits restricted or discouraged, healthcare providers increasingly relied on remote monitoring to assess device function and patient status. This trend continued even after the pandemic as it offered more flexibility in patient care. While these services are not a replacement for in-person procedures, they played a role in patient monitoring and management. COVID-19 had a moderate effect on the market.

Type Outlook

Based on type, the market is classified into single chamber ICDs, dual chamber ICDs, and biventricular devices. The dual chamber ICDs segment acquired a substantial revenue share in the market in 2022. Dual-chamber ICDs have the advantage of monitoring both the atrium and ventricle, which allows for more sophisticated arrhythmia detection algorithms. This improved detection capability can help reduce inappropriate shocks and improve patient outcomes. Many dual-chamber ICDs have pacing capabilities for both the atrium and ventricle. This feature can benefit patients who require physiological pacing to maintain proper heart function, such as those with atrioventricular (AV) block or sick sinus syndrome.

Product Type Outlook

By product type, the market is categorized into transvenous and subcutaneous. In 2022, the transvenous segment held the highest revenue share in the market. Transvenous ICDs suit many patients, including those at risk of sudden cardiac arrest because of various cardiac conditions. This broad patient eligibility expands the potential market for these devices. Ongoing advancements in transvenous ICD technology have led to smaller, more sophisticated devices with improved battery life and advanced arrhythmia detection algorithms. These advancements make transvenous ICDs more appealing to both patients and healthcare providers.



NYHA Class Outlook

On the basis of NYHA class, the market is divided into NYHA class II and NYHA class III. The NYHA class III segment garnered a significant revenue share in the market in 2022. One of the primary indications for ICD implantation is to reduce the risk of sudden cardiac death in heart failure patients at high risk of ventricular arrhythmias. NYHA Class III patients with specific risk factors, such as a reduced left ventricular ejection fraction (LVEF) or a history of ventricular arrhythmias, are considered for ICD therapy to prevent SCD.

End-use Outlook

By end-use, the market is fragmented into hospitals, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the maximum revenue share in the market. Hospitals provide a controlled and sterile environment for ICD implantation procedures, ensuring the highest level of care and safety for patients. Hospitals have cardiac electrophysiologists and specialized cardiac teams with extensive training and expertise in ICD implantation, programming, and follow-up care. Leading hospitals have state-of-the-art facilities, including advanced cardiac catheterization labs and operating rooms, essential for ICD implantation procedures.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. Hospitals, clinics, and other healthcare facilities are well-developed and modernized in North America. Additionally, the region also experiences a high prevalence of cardiovascular diseases (CVD), such as hypertension, necessitating ICDs. The market is further strengthened by significant manufacturers like Medtronic, Abbott, and Boston Scientific Corporation, with Medtronic's launch of extravascular ICDs (EV-ICDs) presenting substantial opportunities. In addition, companies in China, India, and Japan are actively developing and introducing innovative healthcare solutions, driving the development of the regional market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Biotronik SE & Co. KG, Boston Scientific Corporation, MicroPort Scientific Corporation, Stryker Corporation, ZOLL Medical Corporation (Asahi Kasei Corporation), LivaNova PLC, Koninklijke Philips N.V. and Getinge AB.

Strategies deployed in the Market

  • Jul-2023: Abbott Laboratories got approval from the FDA for the AVEIR dual chamber (DR) leadless pacemaker system, an advanced medical device that offers dual-chamber pacing capabilities without the need for traditional leads or wires, improving patient comfort and reducing potential complications.
  • Nov-2021: Koninklijke Philips N.V. acquired Cardiology, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
  • Apr-2021: ZOLL Medical Corporation took over Respicardia, Inc., a medical device company focused on developing innovative therapies for people with central sleep apnea. Through this acquisition, both companies jointly worked together to enhance patient outcomes through the development of groundbreaking therapies for conditions with significant unmet clinical needs.
  • Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favourable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both the organization's portfolio and service platforms.
  • Oct-2020: Abbott Laboratories introduced ICD (Implantable Cardioverter-Defibrillator), a medical device that monitors heart rhythms and delivers shocks to treat life-threatening arrhythmias, and CRT-D (Cardiac Resynchronization Therapy with Defibrillation), an ICD with an added feature to synchronize the contractions of the heart's ventricles, improving heart function in certain patients.
  • Apr-2019: Stryker Corporation launched LIFEPAK® CR2 Defibrillator in the United States, an advanced automated external defibrillator (AED) designed for easy use in emergency cardiac situations. The LIFEPAK CR2 is designed to improve CPR quality and deliver the quickest initial shock during defibrillation, with every aspect tailored to boost user confidence, utilizing connectivity to support comprehensive care in the chain of survival and streamline AED program management for our clients.

Scope of the Study

Market Segments Covered in the Report:

By Type
  • Biventricular Devices
  • Dual Chamber ICDs
  • Single Chamber ICDs
By Product Type
  • Transvenous
  • Subcutaneous
By NYHA Class
  • NYHA Class II
  • NYHA Class III
By End-use
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America- Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe- Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific- LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Abbott Laboratories
  • Medtronic PLC
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Stryker Corporation
  • ZOLL Medical Corporation (Asahi Kasei Corporation)
  • LivaNova PLC
  • Koninklijke Philips N.V.
  • Getinge AB

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Implantable Cardioverter Defibrillator Market, by Type
1.4.2 Global Implantable Cardioverter Defibrillator Market, by Product Type
1.4.3 Global Implantable Cardioverter Defibrillator Market, by NYHA Class
1.4.4 Global Implantable Cardioverter Defibrillator Market, by End-use
1.4.5 Global Implantable Cardioverter Defibrillator Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Implantable Cardioverter Defibrillator Market
Chapter 5. Global Implantable Cardioverter Defibrillator Market, By Type
5.1 Global Biventricular Devices Market, By Region
5.2 Global Dual Chamber ICDs Market, By Region
5.3 Global Single Chamber ICDs Market, By Region
Chapter 6. Global Implantable Cardioverter Defibrillator Market, By Product Type
6.1 Global Transvenous Market, By Region
6.2 Global Subcutaneous Market, By Region
Chapter 7. Global Implantable Cardioverter Defibrillator Market, By NYHA Class
7.1 Global NYHA Class II Market, By Region
7.2 Global NYHA Class III Market, By Region
Chapter 8. Global Implantable Cardioverter Defibrillator Market, By End-use
8.1 Global Hospitals Market, By Region
8.2 Global Ambulatory Surgical Centers Market, By Region
8.3 Global Others Market, By Region
Chapter 9. Global Implantable Cardioverter Defibrillator Market, By Region
9.1 North America Implantable Cardioverter Defibrillator Market
9.1.1 North America Implantable Cardioverter Defibrillator Market, By Type
9.1.1.1 North America Biventricular Devices Market, By Country
9.1.1.2 North America Dual Chamber ICDs Market, By Country
9.1.1.3 North America Single Chamber ICDs Market, By Country
9.1.2 North America Implantable Cardioverter Defibrillator Market, By Product Type
9.1.2.1 North America Transvenous Market, By Country
9.1.2.2 North America Subcutaneous Market, By Country
9.1.3 North America Implantable Cardioverter Defibrillator Market, By NYHA Class
9.1.3.1 North America NYHA Class II Market, By Country
9.1.3.2 North America NYHA Class III Market, By Country
9.1.4 North America Implantable Cardioverter Defibrillator Market, By End-use
9.1.4.1 North America Hospitals Market, By Country
9.1.4.2 North America Ambulatory Surgical Centers Market, By Country
9.1.4.3 North America Others Market, By Country
9.1.5 North America Implantable Cardioverter Defibrillator Market, By Country
9.1.5.1 US Implantable Cardioverter Defibrillator Market
9.1.5.1.1 US Implantable Cardioverter Defibrillator Market, By Type
9.1.5.1.2 US Implantable Cardioverter Defibrillator Market, By Product Type
9.1.5.1.3 US Implantable Cardioverter Defibrillator Market, By NYHA Class
9.1.5.1.4 US Implantable Cardioverter Defibrillator Market, By End-use
9.1.5.2 Canada Implantable Cardioverter Defibrillator Market
9.1.5.2.1 Canada Implantable Cardioverter Defibrillator Market, By Type
9.1.5.2.2 Canada Implantable Cardioverter Defibrillator Market, By Product Type
9.1.5.2.3 Canada Implantable Cardioverter Defibrillator Market, By NYHA Class
9.1.5.2.4 Canada Implantable Cardioverter Defibrillator Market, By End-use
9.1.5.3 Mexico Implantable Cardioverter Defibrillator Market
9.1.5.3.1 Mexico Implantable Cardioverter Defibrillator Market, By Type
9.1.5.3.2 Mexico Implantable Cardioverter Defibrillator Market, By Product Type
9.1.5.3.3 Mexico Implantable Cardioverter Defibrillator Market, By NYHA Class
9.1.5.3.4 Mexico Implantable Cardioverter Defibrillator Market, By End-use
9.1.5.4 Rest of North America Implantable Cardioverter Defibrillator Market
9.1.5.4.1 Rest of North America Implantable Cardioverter Defibrillator Market, By Type
9.1.5.4.2 Rest of North America Implantable Cardioverter Defibrillator Market, By Product Type
9.1.5.4.3 Rest of North America Implantable Cardioverter Defibrillator Market, By NYHA Class
9.1.5.4.4 Rest of North America Implantable Cardioverter Defibrillator Market, By End-use
9.2 Europe Implantable Cardioverter Defibrillator Market
9.2.1 Europe Implantable Cardioverter Defibrillator Market, By Type
9.2.1.1 Europe Biventricular Devices Market, By Country
9.2.1.2 Europe Dual Chamber ICDs Market, By Country
9.2.1.3 Europe Single Chamber ICDs Market, By Country
9.2.2 Europe Implantable Cardioverter Defibrillator Market, By Product Type
9.2.2.1 Europe Transvenous Market, By Country
9.2.2.2 Europe Subcutaneous Market, By Country
9.2.3 Europe Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.3.1 Europe NYHA Class II Market, By Country
9.2.3.2 Europe NYHA Class III Market, By Country
9.2.4 Europe Implantable Cardioverter Defibrillator Market, By End-use
9.2.4.1 Europe Hospitals Market, By Country
9.2.4.2 Europe Ambulatory Surgical Centers Market, By Country
9.2.4.3 Europe Others Market, By Country
9.2.5 Europe Implantable Cardioverter Defibrillator Market, By Country
9.2.5.1 Germany Implantable Cardioverter Defibrillator Market
9.2.5.1.1 Germany Implantable Cardioverter Defibrillator Market, By Type
9.2.5.1.2 Germany Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.1.3 Germany Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.1.4 Germany Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.2 UK Implantable Cardioverter Defibrillator Market
9.2.5.2.1 UK Implantable Cardioverter Defibrillator Market, By Type
9.2.5.2.2 UK Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.2.3 UK Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.2.4 UK Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.3 France Implantable Cardioverter Defibrillator Market
9.2.5.3.1 France Implantable Cardioverter Defibrillator Market, By Type
9.2.5.3.2 France Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.3.3 France Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.3.4 France Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.4 Russia Implantable Cardioverter Defibrillator Market
9.2.5.4.1 Russia Implantable Cardioverter Defibrillator Market, By Type
9.2.5.4.2 Russia Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.4.3 Russia Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.4.4 Russia Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.5 Spain Implantable Cardioverter Defibrillator Market
9.2.5.5.1 Spain Implantable Cardioverter Defibrillator Market, By Type
9.2.5.5.2 Spain Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.5.3 Spain Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.5.4 Spain Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.6 Italy Implantable Cardioverter Defibrillator Market
9.2.5.6.1 Italy Implantable Cardioverter Defibrillator Market, By Type
9.2.5.6.2 Italy Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.6.3 Italy Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.6.4 Italy Implantable Cardioverter Defibrillator Market, By End-use
9.2.5.7 Rest of Europe Implantable Cardioverter Defibrillator Market
9.2.5.7.1 Rest of Europe Implantable Cardioverter Defibrillator Market, By Type
9.2.5.7.2 Rest of Europe Implantable Cardioverter Defibrillator Market, By Product Type
9.2.5.7.3 Rest of Europe Implantable Cardioverter Defibrillator Market, By NYHA Class
9.2.5.7.4 Rest of Europe Implantable Cardioverter Defibrillator Market, By End-use
9.3 Asia Pacific Implantable Cardioverter Defibrillator Market
9.3.1 Asia Pacific Implantable Cardioverter Defibrillator Market, By Type
9.3.1.1 Asia Pacific Biventricular Devices Market, By Country
9.3.1.2 Asia Pacific Dual Chamber ICDs Market, By Country
9.3.1.3 Asia Pacific Single Chamber ICDs Market, By Country
9.3.2 Asia Pacific Implantable Cardioverter Defibrillator Market, By Product Type
9.3.2.1 Asia Pacific Transvenous Market, By Country
9.3.2.2 Asia Pacific Subcutaneous Market, By Country
9.3.3 Asia Pacific Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.3.1 Asia Pacific NYHA Class II Market, By Country
9.3.3.2 Asia Pacific NYHA Class III Market, By Country
9.3.4 Asia Pacific Implantable Cardioverter Defibrillator Market, By End-use
9.3.4.1 Asia Pacific Hospitals Market, By Country
9.3.4.2 Asia Pacific Ambulatory Surgical Centers Market, By Country
9.3.4.3 Asia Pacific Others Market, By Country
9.3.5 Asia Pacific Implantable Cardioverter Defibrillator Market, By Country
9.3.5.1 China Implantable Cardioverter Defibrillator Market
9.3.5.1.1 China Implantable Cardioverter Defibrillator Market, By Type
9.3.5.1.2 China Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.1.3 China Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.1.4 China Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.2 Japan Implantable Cardioverter Defibrillator Market
9.3.5.2.1 Japan Implantable Cardioverter Defibrillator Market, By Type
9.3.5.2.2 Japan Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.2.3 Japan Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.2.4 Japan Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.3 India Implantable Cardioverter Defibrillator Market
9.3.5.3.1 India Implantable Cardioverter Defibrillator Market, By Type
9.3.5.3.2 India Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.3.3 India Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.3.4 India Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.4 South Korea Implantable Cardioverter Defibrillator Market
9.3.5.4.1 South Korea Implantable Cardioverter Defibrillator Market, By Type
9.3.5.4.2 South Korea Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.4.3 South Korea Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.4.4 South Korea Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.5 Singapore Implantable Cardioverter Defibrillator Market
9.3.5.5.1 Singapore Implantable Cardioverter Defibrillator Market, By Type
9.3.5.5.2 Singapore Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.5.3 Singapore Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.5.4 Singapore Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.6 Malaysia Implantable Cardioverter Defibrillator Market
9.3.5.6.1 Malaysia Implantable Cardioverter Defibrillator Market, By Type
9.3.5.6.2 Malaysia Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.6.3 Malaysia Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.6.4 Malaysia Implantable Cardioverter Defibrillator Market, By End-use
9.3.5.7 Rest of Asia Pacific Implantable Cardioverter Defibrillator Market
9.3.5.7.1 Rest of Asia Pacific Implantable Cardioverter Defibrillator Market, By Type
9.3.5.7.2 Rest of Asia Pacific Implantable Cardioverter Defibrillator Market, By Product Type
9.3.5.7.3 Rest of Asia Pacific Implantable Cardioverter Defibrillator Market, By NYHA Class
9.3.5.7.4 Rest of Asia Pacific Implantable Cardioverter Defibrillator Market, By End-use
9.4 LAMEA Implantable Cardioverter Defibrillator Market
9.4.1 LAMEA Implantable Cardioverter Defibrillator Market, By Type
9.4.1.1 LAMEA Biventricular Devices Market, By Country
9.4.1.2 LAMEA Dual Chamber ICDs Market, By Country
9.4.1.3 LAMEA Single Chamber ICDs Market, By Country
9.4.2 LAMEA Implantable Cardioverter Defibrillator Market, By Product Type
9.4.2.1 LAMEA Transvenous Market, By Country
9.4.2.2 LAMEA Subcutaneous Market, By Country
9.4.3 LAMEA Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.3.1 LAMEA NYHA Class II Market, By Country
9.4.3.2 LAMEA NYHA Class III Market, By Country
9.4.4 LAMEA Implantable Cardioverter Defibrillator Market, By End-use
9.4.4.1 LAMEA Hospitals Market, By Country
9.4.4.2 LAMEA Ambulatory Surgical Centers Market, By Country
9.4.4.3 LAMEA Others Market, By Country
9.4.5 LAMEA Implantable Cardioverter Defibrillator Market, By Country
9.4.5.1 Brazil Implantable Cardioverter Defibrillator Market
9.4.5.1.1 Brazil Implantable Cardioverter Defibrillator Market, By Type
9.4.5.1.2 Brazil Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.1.3 Brazil Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.1.4 Brazil Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.2 Argentina Implantable Cardioverter Defibrillator Market
9.4.5.2.1 Argentina Implantable Cardioverter Defibrillator Market, By Type
9.4.5.2.2 Argentina Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.2.3 Argentina Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.2.4 Argentina Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.3 UAE Implantable Cardioverter Defibrillator Market
9.4.5.3.1 UAE Implantable Cardioverter Defibrillator Market, By Type
9.4.5.3.2 UAE Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.3.3 UAE Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.3.4 UAE Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.4 Saudi Arabia Implantable Cardioverter Defibrillator Market
9.4.5.4.1 Saudi Arabia Implantable Cardioverter Defibrillator Market, By Type
9.4.5.4.2 Saudi Arabia Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.4.3 Saudi Arabia Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.4.4 Saudi Arabia Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.5 South Africa Implantable Cardioverter Defibrillator Market
9.4.5.5.1 South Africa Implantable Cardioverter Defibrillator Market, By Type
9.4.5.5.2 South Africa Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.5.3 South Africa Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.5.4 South Africa Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.6 Nigeria Implantable Cardioverter Defibrillator Market
9.4.5.6.1 Nigeria Implantable Cardioverter Defibrillator Market, By Type
9.4.5.6.2 Nigeria Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.6.3 Nigeria Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.6.4 Nigeria Implantable Cardioverter Defibrillator Market, By End-use
9.4.5.7 Rest of LAMEA Implantable Cardioverter Defibrillator Market
9.4.5.7.1 Rest of LAMEA Implantable Cardioverter Defibrillator Market, By Type
9.4.5.7.2 Rest of LAMEA Implantable Cardioverter Defibrillator Market, By Product Type
9.4.5.7.3 Rest of LAMEA Implantable Cardioverter Defibrillator Market, By NYHA Class
9.4.5.7.4 Rest of LAMEA Implantable Cardioverter Defibrillator Market, By End-use
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Product Launches and Product Expansions:
10.1.5.2 Trails and Approvals:
10.1.6 SWOT Analysis
10.2 Medtronic PLC
10.2.1 Company overview
10.2.2 Financial Analysis
10.2.3 Segmental and Regional Analysis
10.2.4 Research & Development Expenses
10.2.5 SWOT Analysis
10.3 Biotronik SE & Co. KG
10.3.1 Company Overview
10.3.2 SWOT Analysis
10.4 Boston Scientific Corporation
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 SWOT Analysis
10.5 MicroPort Scientific Corporation
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 SWOT Analysis
10.6 Stryker Corporation
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Product Launches and Product Expansions:
10.6.6 SWOT Analysis
10.7 ZOLL Medical Corporation (Asahi Kasei Corporation)
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 Recent strategies and developments:
10.7.5.1 Acquisition and Mergers:
10.7.6 SWOT Analysis
10.8 LivaNova PLC
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.8.5 SWOT Analysis
10.9 Koninklijke Philips N.V.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Segmental and Regional Analysis
10.9.4 Research & Development Expense
10.9.5 Recent strategies and developments:
10.9.5.1 Acquisition and Mergers:
10.9.6 SWOT Analysis
10.10. Getinge AB
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 SWOT Analysis
Chapter 11. Winning imperatives of Implantable Cardioverter Defibrillator Market

Companies Mentioned

  • Abbott Laboratories
  • Medtronic PLC
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Stryker Corporation
  • ZOLL Medical Corporation (Asahi Kasei Corporation)
  • LivaNova PLC
  • Koninklijke Philips N.V.
  • Getinge AB

Methodology

Loading
LOADING...

Related Topics

Related Reports

Implantable Cardioverter Defibrillators Market by Product Type, by Type, by NYHA Class, by End-User, and By Region - Product Image

Implantable Cardioverter Defibrillators Market by Product Type, by Type, by NYHA Class, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Implantable Cardioverter Defibrillators Market Size, Share & Trends Analysis Report by NYHA Class (NYHA Class I, NYHA Class II), End-use (Hospitals, Ambulatory Surgical Centers), Product Type, Type, Region, and Segment Forecasts, 2024-2030 - Product Image

Implantable Cardioverter Defibrillators Market Size, Share & Trends Analysis Report by NYHA Class (NYHA Class I, NYHA Class II), End-use (Hospitals, Ambulatory Surgical Centers), Product Type, Type, Region, and Segment Forecasts, 2024-2030

  • Report
  • 174 Pages
  • Global
From
Implantable Cardioverter Defibrillator Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Implantable Cardioverter Defibrillator Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 182 Pages
  • Global
From
Implantable Cardioverter Defibrillators Market by Implantation Location, Product, End User - Global Forecast 2025-2030 - Product Image

Implantable Cardioverter Defibrillators Market by Implantation Location, Product, End User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Implantable Cardioverter Defibrillators (ICD) - Global Strategic Business Report - Product Image

Implantable Cardioverter Defibrillators (ICD) - Global Strategic Business Report

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.